Completion report on merger, etc. (asset transfer)

What happened

Completion Report on Merger, etc. (Asset Transfer) 6.0 Ascendio Co., Ltd.

To the Governor of the Financial Supervisory Service August 21, 2026

Company name: Ascendio Co., Ltd. Representative Director: Shin Min-gyu Head office address: 8F, 729 Eonju-ro (Nonhyeon-dong, Masters Building), Gangnam-gu, Seoul (Phone) 1544-0332 (Website) http://ascendio.co.kr Preparer: (Title) Representative Director (Name) Shin Min-gyu (Phone) 1544-0332

I. Schedule

This report is a completion report relating to the July 7, 2026 material event report (decision to acquire tangible assets). As of the filing date, the Company reports that this transaction has been completed following completion of the title registration between the Company and the transferor.

1. Overview of the transaction Asset classification: Land/buildings Asset acquired: 160-14 Sindang-dong and 2 other lots and buildings, Jung-gu, Seoul Transferor: Kyungnam Pharmaceutical Co., Ltd. Transferee: Ascendio Co., Ltd. Acquisition amount: KRW 13,100,369,000 Note: The acquisition amount above is the contract price under the sale agreement, excluding VAT, taxes/dues, and fees.

2. Asset acquisition schedule External valuation period: 2026.06.22 ~ 2026.07.07 (Seongwoon Accounting Corporation) Board resolution date: 2026.07.07 Material event report filing date: 2026.07.07 Asset transfer agreement execution date: 2026.07.07 Purchase price payment date: 2026.08.10 In-kind rights-offering payment date / asset transfer completion date: 2026.08.20 Note: Because the asset transfer was completed by having the subscriber in the third-party allotment rights offering (2026.07.07) contribute the real property in kind as payment for the offering, pursuant to court approval, completion is based on the date title registration was completed.

II. Changes in the Largest Shareholder's Equity Stake

Through the in-kind contribution of the rights-offering payment via this asset transfer, the Company's largest shareholder changed, as of the payment date, to Kyungnam Pharmaceutical Co., Ltd. and 1 other. Before the asset transfer: Kiwi 1st Union, 1,875,290 shares, 46.30% (total 1,875,290 shares, 46.30%) After the asset transfer: Kyungnam Pharmaceutical Co., Ltd., 3,246,683 shares, 44.50%; Kiwi 1st Union, 1,875,290 shares, 25.70% (total 5,121,973 shares, 70.20%)

III. Exercise of Appraisal Rights: Not applicable IV. Creditor Protection: Not applicable V. Related Litigation: Not applicable VI. New Share Allotment, etc.: Not applicable

VII. Summary Financial Information Before/After the Merger, etc. (unit: KRW million) Before asset transfer / Change / After asset transfer: Current assets: 15,461 / - / 15,461 Non-current assets: 6,418 / 13,100 / 19,518 Total assets: 21,879 / 13,100 / 34,979 Current liabilities: 2,750 / - / 2,750 Non-current liabilities: 228 / - / 228 Total liabilities: 2,977 / - / 2,977 Capital: 10,125 / 8,117 / 18,242 Total equity: 18,902 / 13,100 / 32,002 Total liabilities and equity: 21,879 / 13,100 / 34,979 Note: The above financial information is based on consolidated financial statements as of the half-year reporting date (June 30, 2026), and simply reflects the amounts directly attributable to this asset acquisition; actual financial statements may differ depending on the external auditor's audit or review results.